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Identity 
Other names: ARMD7; HtrA; L56; ORF480; PRSS11 
HGNC (Hugo): HTRA1 
Location: 10q26.13 
Local order: Genes flanking HTRA1 in centromere to 
telomere direction: 
- PLEKHA1: pleckstrin homology domain-containing 
family A (phosphoinositide-binding specific) member 
1; 
- ARMS2/LOC387715: age-related maculopathy 
susceptibility 2 (hypothetical protein); 
- HTRA1; 
- DMBT1: deleted in malignant brain tumors; 
- C10orf120/LOC399814: chromosome 10 open 
reading frame (hypothetical protein). 
Note 
Abberrations on 10q26.3 are reported to be associated 
with ovarian cancer. The 10q26.3 region shows high 
frequency of deletion in ovarian cancer. 
Genetic variations on chromosome 10q26 (outside 
variations in the complement genes) are associated with 
an increased risk of the development of AMD (age-
related macular degeneration). 
 
Figure 1. Localization and schematic organization of the HTRA1 gene on chromosome 10. The numbers indicate the length in kilo 
bases. Red boxes represent exons. Black boxes indicate untranslated regions. 
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Several single-nucleotide polymorphisms (SNPs) of the 
ARMS2/HTRA1 region of chromosome 10q26 have 
been identified. They contribute to the development of 
typical neovascular AMD, polypoidal choroidal 
vasculopathy (PCV), which is classified as a subtype of 
neovascular AMD, and nonneovascular AMD as well 
(Cameron et al., 2007; Gotoh et al., 2010; Tong et al., 
2010; Friedrich et al., 2011). 
DNA/RNA 
Description 
The gene encompasses 53384 bases of DNA. The 
coding part is composed of nine exons. 
Transcription 
HTRA1 mRNA product, length of 2138 bases, has an 
open frame of 1443 bp. The gene encodes a 50 kDa 
polypeptide of 480 amino acids residues. 
A single-nucleotide polymorphism (SNP) rs11200638 
located in the HTRA1 promoter has been found in 
AMD (age-related macular degeneration) patients. The 
sequence change is located 512 basepairs upstream of 
the transcriptional start site of the HTRA1 gene (-
512G/A) within a CpG island. It resides within the 
putative binding sites for transcription factors, 
AP2alpha (adaptor-related protein complex 2alpha) and 
SRF (serum response factor) (Yang et al., 2006; 
DeWan et al., 2006). Much debate exists regarding the 
functional significance of the HTRA1 promoter SNP 
and its influence on the HTRA1 gene expression. It was 
demonstrated that the HTRA1 promoter SNP is 
associated with the enhanced expression of the HTRA1 
gene in lymphocytes and retinal pigment epithelium 
from AMD patients (Yang et al., 2006; DeWan et al., 
2006). An et al. (2010) showed that increased 
expression of HTRA1 in retinal pigment epithelium 
cells form AMD patients harbouring homozygous risk 
genotype in comparison to wild type genotype. 
However, two independent studies did not show any 
influence of the risk variant on the HTRA1 expression 
in human lymphocytes and retina (Kanda et al., 2007; 
Chowers et al., 2008). Moreover, Kanda et al. (2010) 
did not find association between the rs11200638 SNP 
and steady-state expression of HTRA1 in retina of 
AMD patients. Results of reporter gene assays with 
HTRA1 promoter sequence provide no evidence for the 
influence of the rs1120638 SNP on the HTRA1 
promoter activity (Friedrich et al., 2011). Friedrich et 
al. (2011) revealed also the presence of a Muller glia-
specific cis-regulatory region located between -3550 
and -2770 bp upstream of the HTRA1 transcription 
start site. 
Pseudogene 
No pseudogenes have been identified. 
Protein 
Note 
HtrA1 protein belongs to the HtrA family of proteins. 
Members of the family are homologs of the HtrA 
protein from the bacterium Escherichia coli. They are 
evolutionarily conserved ATP-independent serine 
proteases, widely distributed from bacteria to humans. 
Structurally, the HtrA proteins are characterized by the 
presence of a trypsin-like protease domain and at least 
one PDZ domain at the C-terminus. The defence 
against cellular stresses inducing abberrations in 
protein structure is believed to be a general function of 
HtrAs (reviewed by Clausen et al., 2002). At least four 
human homologous HtrA proteins have been identified. 
They are involved in maintenance of mitochondrial 
homeostasis, apoptosis and cell signaling and 
disturbances in their functions may contribute to the 
development of several diseases including cancer, 
arthritis and neurodegenerative disorders (reviewed by 
Zurawa-Janicka et al., 2010). HTRA1 was originally 
identified as a gene downregulated in SV40-
transformed fibroblasts (Zumbrunn and Trueb, 1996). 
Description 
The HTRA1 gene encodes a polypeptide of 480 aa and 
of a mass of approximately 50 kDa. 
The full-length HtrA1 protein contains a signal 
secretory peptide at the N-terminus (residues 1-22), a 
domain with homology to the insulin-like growth factor 
binding proteins (residues 25-111), a Kazal-type 
inhibitor motif (residues 115-135), and the 
evolutionarily conserved trypsin-like domain (residues 
206-364) with the amino acid residues of serine 
protease catalytic triad (H220, D250, S328), and the 
PDZ domain (residues 382-473) at the C-terminus. 
 
Figure 2. Domain organization of human HtrA1 protein. SP: signal peptide, IGF-BD: domain with homology to insulin-like growth 
factor binding proteins, KM: Kazal type serine protease inhibitor motif, PROTEOLYTIC: trypsin-like domain, PDZ: PDZ domain. Amino 
acid residues of the HtrA1 catalytic triad are marked (numbers indicate the position of the given residue in a polypeptide chain). 
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Under treatment of ovarian cancer cells with 
chemotherapeutic agents (cisplatin, paclitaxel) a 
removal of the N-terminal Mac25 domain was 
observed. The resulting product, mass of 35 kDa, 
expressed more active phenotype than the full-length 
protein (Chien et al., 2006). The proteolytic processing 
is believed to be an autocatalytic process since the 
catalytically inactive mutant did not undergo such 
modification. 
The processed form of HtrA1, mass of 29 kDa was 
detected in CaSki cells (human cervical cancer line) 
and in 293T cells (human embryonic kidney line). The 
29 kDa product was found to be a predominant active 
form in the nuclear fraction (Clawson et al., 2008). 
The lower molecular weight products were also 
generated under overproduction of proteolytically 
active HtrA1 in heterologous expression systems (Hu et 
al., 1998). 
Expression 
HTRA1 is widely expressed in human tissues. High 
expression was detected in secretory breast epithelium, 
duct cells of liver, kidney tubules of cortex and in the 
glandular epithelium of proliferating endometrium. The 
highest expression was detected in mature layers of 
epidermis (De Luca et al., 2003). 
It was demonstrated that HTRA1 expression in 
glandular and stromal cells increases gradually across 
menstrual cycle and reaches the maximum level at the 
mid- and late secretory phases (Nie et al., 2006). It was 
also reported that HTRA1 expression changes during 
pregnancy both in placental and endometrial cells. Up-
regulation of HTRA1 was observed in endometrial 
glands and decidual cells during preparation of 
endometrium for embryo implantation and during the 
first trimester of placentation (Nie et al., 2006). 
However, the highest expression of HTRA1 was 
detected in placenta in the third trimester of gestation 
(De Luca et al., 2004). These data suggest an important 
role of HtrA1 in placenta development and function. 
Changes in HTRA1 expression were observed in 
response to stress-inducing agents. Upon treatment of 
ovarian cancer cells expressing HTRA1 with the 
commonly used chemotherapeutics the HtrA1 protein 
level estimated by the Western blotting technique was 
increased (Chien et al., 2006). 
Abnormal expression of the gene is associated with 
several diseases, including arthritis and many types of 
cancers. 
Localisation 
HtrA1 is classified as a secreted protein. However, 
processed forms of HtrA1 have been found in the 
cytoplasm and in the nuclear fraction (Clawson et al., 
2008; Chien et al., 2009; He et al., 2010). 
Function 
HtrA1 acts as an ATP-independent serine protease. 
HtrA1 has been shown to function as a regulator of 
TGF-beta signaling. HtrA1 binds to several members of 
the TGF-beta proteins family, including TGF-beta1, 
TGF-beta2, BMP2, BMP4, activin and Gdf5, and 
suppresses signal transduction mediated by these 
extracellular cytokines (Oka et al., 2004). It was 
demonstrated that the proteolytic activity of HtrA1 is 
indispensable for this inhibitory function (Oka et al., 
2004). Recent studies showed also that TGF-beta1 is a 
substrate for HtrA1 in vitro (Launay et al., 2008). 
However, a hypothesis that degradation of TGF-beta 
proteins is the underlying mechanism of TGF-beta 
signaling regulation by HtrA1 needs further studies. 
HtrA1 is involved in the programmed cell death, 
apoptosis. Treatment of the ovarian cancer cells with 
cisplatin or paclitaxel resulted in upregulation of HtrA1 
expression. Under these conditions HtrA1 underwent 
autocatalytic activation resulting in activation of 
caspases 3 and 7 associated with apoptotic cell death. 
However, the mechanism of the process is unknown 
and needs to be elucidated (Chien et al., 2006). 
HtrA1 is implicated in anoikis, a cell death induced by 
anchorage-dependent cells detaching from the 
surrounding extracellular matrix. Resistance to anoikis 
is a common feature of cancer cells and contributes to 
metastasis. HtrA1 regulates anoikis by modulating the 
EGFR/AKT pathway (He et al., 2010). HtrA1 binds to 
EGFR and inhibits EGRF/AKT pathway in a protease-
dependent manner. It was demonstrated that HtrA1 
expression was upregulated and underwent 
autocatalytic activation in response to loss of anchorage 
in suspended culture of ovarian cancer cells. Enhanced 
expression of HtrA1 in ovarian cancer cells suppressed 
EGFR/AKT signaling, which contributed to increased 
cell death, whereas downregulation of the gene 
attenuated anoikis in vitro and also promoted peritoneal 
dissemination of ovarian cancer cells in mouse model 
(He et al., 2010). 
Homology 
The HtrA1 protein is evolutionarily conserved among 
mammalian species. At the amino acid level the human 
HtrA1 shares a 98% identity with its orthologues from 
mouse, cow, rabbit, guinea pig (Hu et al., 1998) and 
hamster (Zurawa-Janicka et al., 2008). At least three 
paralogs of HtrA1 have been identified in humans: 
HtrA2 (Omi), HtrA3 (PRSP) and HtrA4. HtrA1 protein 
shares the 54, 58 and 54% identity with HtrA2, HtrA3 
and HtrA4 respectively. The homology between HtrA1 
and its paralogs HtrA2, HtrA3 and HtrA4 reaches 75, 
74 and 71%, respectively. 
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Figure 3. Distribution of HTRA1 mutations associated with CARASIL. Missense mutations are marked in red and nonsense 
mutations are marked in blue. SP: signal peptide, IGF-BD: domain with homology to insulin-like growth factor binding proteins, KM: Kazal 




Two missense mutations G754A (the amino acid 
substitution A252T) and G889A (the amino acid 
substitution V297M) and two nonsense mutations 
C904T and C1108T (resulting in a stop codon at 
position 302 and 370, respectively) localized in exon 3 
and 4, associated with the development of cerebral 
autosomal recessive arteriopathy with subcortical 
infarts and leukoencephalopathy (CARASIL) have 
been identified in the HTRA1 gene (Hara et al., 2009). 
The nonsense mutation C1108T resulted in the loss of 
protein product by nonsense-mediated mRNA decay. 
Three other mutations reduced the HtrA1 proteolytic 
activity in vitro and also failed to repress the TGF-beta 






The HTRA1 expression was found to be down-
regulated in many types of cancers such as melanoma 
(Baldi et al., 2002), glioma (Kotliarov et al., 2006), 
mesothelioma (Baldi et al., 2008), ovarian tumors 
(Chien et al., 2004; Chien et al., 2006; Narkiewicz et 
al., 2008), endometrial (Bowden et al., 2006; 
Narkiewicz et al., 2009) and lung cancers (Esposito et 
al., 2006) as well as in the ovarian, some brain, breast 
and liver cancer cell lines (Chien et al., 2004). 
The HTRA1 expression was reported to be down-
regulated in ovarian cancer cells lines and tumors 
(Chien et al., 2004; Chien et al., 2006; Narkiewicz et 
al., 2008). In the primary ovarian tumors 
downregulation of the HTRA1 expression was 
correlated with a loss of heterozygosity of the gene and 
hypermethylation (Chien et al., 2004). Moreover, a 
progressive decrease of HTRA1 expression with degree 
of malignancy has been observed (Narkiewicz et al., 
2008). 
The HTRA1 mRNA and HtrA1 protein levels were also 
significantly decreased in the endometrial cancer 
(Bowden et al., 2006; Narkiewicz et al., 2009). The 
HTRA1 level decreased with increasing grades of 
endometrial cancer (Bowden et al., 2006). A significant 
negative correlation between HtrA1 and TGF-beta1 
protein levels found in endometrial cancer suggests that 
HtrA1 is involved in regulation of the TGF-beta1 
signaling pathway in this type of cancer (Narkiewicz et 
al., 2009). 
The decreased expression of HTRA1 was found to be 
correlated with metastasis in melanoma and lung 
cancer. HTRA1 expression was significantly lower in 
the lymph node metastases than in primary tumors 
(Baldi et al., 2002; Esposito et al., 2006). 
Prognosis 
Downregulation of the HTRA1 gene, frequently 
observed in ovarian cancer was correlated with poor 
clinical response to chemoteraphy. In patients with 
primary ovarian tumors higher expression of HTRA1 
corresponded to a better response to platinum-based 
chemotherapy. Similar clinical response to the 
cisplatin-based therapy was observed in a group of 
patients with gastric tumors (Chien et al., 2006). Loss 
of HtrA1 was also correlated with poor prognosis in 
glioma (Kotliarov et al., 2006) and mesothelioma 
(Baldi et al., 2008). 
Cytogenetics 
A loss of heterozygosity of the gene was observed in 
ovarian cancer (Chien et al., 2004). In the primary 
ovarian cancers HTRA1 expression was diminished or 
lost in 59% of cases. Analysis of tumor samples 
revealed that decreased expression of HTRA1 was 
associated with the loss of heterozygosity of the gene. 
On the other hand the HTRA1 locus was subjected to 
hypermethylation which might be another mechanism 
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of the HTRA1 gene silencing observed in ovarian 







HtrA1 is believed to function as a tumor supressor, 
promoting cell death due to its proapoptotic function 
and implication in anoikis. Thereby downregulation of 
the HTRA1 gene expression contributes to survival of 
cancer cells in vitro, and facilitates tumor growth, 
malignant progression and metastasis in vivo (Baldi et 
al., 2002; Chien et al., 2004; Chien et al., 2006; He et 
al., 2010). Lower expression of HTRA1 in ovarian and 
gastric tumors contributes to poor response to 
platinum-based chemotherapy (Chien et al., 2006). 
Age-related macular degeneration 
(AMD) 
Note 
Several single nucleotide polymorphisms (SNP) 
associated with the development of AMD have been 
identified within the HTRA1 gene. Among them, the 
rs11200638 (G>A) SNP serves as a strong marker for 
AMD contributing to increased risk for the disease and 
association of the rs11200638 SNP with susceptibility 
to AMD in studies of Caucasian and Asian populations 
have been revealed (DeWan et al., 2006; Kondo et al., 
2007; Yoshida et al., 2007; Cameron et al., 2007; 
DeAngelis et al., 2008; Tong et al., 2010). The SNP is 
located in the HTRA1 promoter, however its influence 
on HTRA1 expression in AMD patients is a matter of 
controversy (Yang et al., 2006; DeWan et al., 2006; 
Kanda et al., 2007; Kanda et al., 2010; Chowers et al., 
2008; Friedrich et al., 2011; An et al., 2010). 
The rs2672598 (C>T) SNP found within the promoter 
region was associated with decreased risk for 
neovascular AMD (DeAngelis et al., 2008). 
Two minor SNPs, rs1049331 (C>T) and rs2293870 
(G>T,C) were found within the coding region of 
HTRA1 and they resulted in synonymous substitutions 
in amino acid sequence. They were associated with an 
increased risk of neovascular AMD development 
(DeAngelis et al., 2008). 
The rs2672587 (C>G) SNP was also demonstrated to 
be significantly associated with the development of 
neovascular AMD in Japanese patients (Goto et al., 
2009). 
Recent studies by An et al. (2010) showed that various 
regulators of the complement pathway such as 
vitronectin, clusterin, fibronectin are substrates for 
HtrA1 in vitro. It suggests an association between 
HtrA1 and the complement pathway in AMD (An et 
al., 2010). 
Disease 
AMD is a leading cause of irreversible blindness in the 
world and is associated with degeneration of the central 
retina. The neovascular, wet type of AMD is prevalent 
among Asian population, whereas Caucasians are 
predominantly affected by nonneovascular, dry form of 
AMD. Environmental and genetic risk factors have 
been found to be involved in the pathogenesis of AMD. 
Results of genetic analysis have demonstrated that 
susceptibility to AMD is strongly associated with 
genetic variants at chromosomes 1q31, encompassing 
the complement factor H (CFH) gene and 10q26, 
encompassing ARMS2/HTRA1 loci. 
Alzheimer's disease (AD) 
Note 
Neuropathological analysis of brain samples from AD 
patients revealed colocalization of HtrA1 with beta-
amyloid deposits. HtrA1 was detected in astrocytes and 
cortical neurons of AD patients in contrast to neuroglial 
cells of the healthy adult brains. Grau et al. (2005) 
demonstrated that HtrA1 performs in vitro proteolysis 
of various fragments of amyloid precursor protein, 
including beta40 and beta42. Using human astrocytoma 
cell line they showed that inhibition of HtrA1 
proteolytic activity resulted in accumulation of beta-
amyloid in cell culture supernatant. These results 
indicate that HtrA1 is involved in metabolism of beta-
amyloid proteins and suggest that HtrA1 could protect 
against the development of AD (Grau et al., 2005). 
Disease 
AD is a neurodegenerative disorder characterized by 
progressive memory loss and cognitive decline. The 
pathological features of AD are neuronal and synaptic 
loss, formation of neurofibrillary tangles within 
neurons and accumulation of extracellular neurotoxic 
deposites of amyloid beta protein (Abeta), called senile 
plaques. Major components of senile plagues are 
Abeta40 and Abeta42, exhibiting tendency to 
aggregation and generated by hydrolysis of amyloid 
precursor protein (APP) amyloid in beta-amyloid 
pathway involving secretase beta and gamma. 
Arthritic diseases (osteoarthritis and 
rheumatoid arthritis) 
Note 
Elevated level of HtrA1 was detected in cartilage of 
joints from patients with osteoarthritis (Hu et al., 1998) 
and in synovial fluid derived from patients with 
rheumatoid arthritis (Grau et al., 2006).  
HtrA1 is believed to be involved in pathogenesis of 
arthritic disorders due to inhibition of TGF-beta 
signalling, proteolysis of extracellular matrix proteins 
and components of cartilage, and activation of 
metalloproteases. TGF-beta proteins are implicated in 
the maintenance of a normal joint cartilage by 
preventing joint chondrocytes from terminal 
differentiation. HtrA1 inhibits TGF-beta signaling and 
thereby might contribute to the replacement of articular 
cartilage by bone (Tsuchiya et al., 2005). Several 
proteins of the extracellular matrix and components of 
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cartilage such as aggrecan, decorin, fibromodulin, 
fibronectin, soluble type II collagen are substrates of 
the protease in vitro (Tsuchiya et al., 2005; Grau et al., 
2006; Hadfield et al., 2008). HtrA1 is involved in 
activation of matrix metalloproteases -1 and -3 which 
contribute to extracellular matrix destruction (Grau et 
al., 2006). 
Disease 
Rheumatoid arthritis (RA) is a chronic, systemic 
autoimmune inflammatory disease characterized by a 
deforming symmetrical polyarthritis of varying extent 
and severity, articular cartilage loss and erosion of 
juxta-articular bone. RA can occur at any age. 
Osteoarthritis (OA) is a degenerative joint disease 
characterized by loss of articular chondrocytes and 
destruction of extracellular matrix components, leading 
to cartilage degeneration and restriction of joint 
mobility. The prevalence of OA increases with age. 
Cerebral autosomal recessive 
arteriopathy with subcortical infarts and 
leukoencephalopathy (CARASIL) 
Note 
Hara et al. (2009) showed that CARASIL is associated 
with mutations in the coding sequence of the HTRA1 
gene. Two missense mutations and two nonsense 
mutations have been identified in CARASIL patients. 
These mutations have been found to be liable for the 
loss of HtrA1 protein and generation of the HtrA1 
variants with a reduced activity in vitro and lacking the 
ability to inhibit signalling mediated by TGF-beta 
proteins. Hara et al. (2009) postulated that the increased 
TGF-beta signalling, associated with the reduced 
activity of HtrA1 protease in the cerebral small arteries, 
contributes to the development of CARASIL. 
Disease 
CARASIL is a hereditary form of ischemic, 
nonhypertensive, cerebral small-vessel disease with 
associated deterioration in brain functions, progressive 
dementia, alopecia, spondylosis and disk degeneration 
linked to osteophytosis. Histopathologically, CARASIL 
is characterized by intense arteriosclerosis, limited to 
cerebral small arteries, associated with intimal 
thickening and dense collagen fibres, loss of vascular 




No breakpoints described so far. 
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